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SIONS: The risk of AVB in SND patients is increased in cases
with AF history. The strategy of primary AAI implantation in
SND is cost-saving in patients with no history of AF but no such
proﬁt is observed in the group with the history of AF.
CARDIOVASCULAR
CARDIOVASCULAR—Quality of Life/Utility/Preference
Studies
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SYMPTOMATOLOGY
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OBJECTIVES: The objective of our study was to assess 
depressive symptomatology (DS) among CVD affected women.
METHODS: Symptomatic women patients suffering from CVD
(CEAP C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
completed a self-questionnaire including the CES-D scale at day
0, day three and seven. A score over 17 indicates a possible DS,
a score over 23 indicates a probable DS. RESULTS: This analy-
sis includes the ﬁrst 371 patients assessed at day 0, D3 and D7.
The mean age was 45.0 years old (SD = 11, n = 370). The mean
CES-D scores at day 0, D3 and D7, were respectively 14.9 (SD
= 10.2), 13.7 (SD = 8.9) and 12.8 (SD = 10.1). The results high-
light a possible DS in our population (score over 17) for 36.3%,
32.3% and 29.0% respectively at day 0, D3 and D7 (p < 0.01,
n = 328). Patients that have expressed a probable DS were 74 at
inclusion (22.0% of the population); they show a signiﬁcant
improvement of their status assessed by CES-D. From those 74
patients, only 50 still had a score over 23 at D3 and 46 at D7
showing a decrease of 37.8% of the number of patients express-
ing a probable DS (p < 0.0001, n = 74, matched test J0-J7).
CONCLUSIONS: In the study of Rield assessing depressive
symptoms in older women (age 65 to 75), 23.1% of women
reported high depressive symptoms (CES-D score over 16). CVD
result in psychological effects that seriously affect patients’ lives.
Following patient management and the use of a phlebotropic
drug the prevalence of DS decreased rapidly showing evidence
of the relevance of this management.
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OBJECTIVES: The objective of our study was to describe the
proﬁle of French women suffering from Chronic venous disease
(CVD). METHODS: Symptomatic women patients suffering
from CVD (CEAP clinical classes C0 to C4), aged over 18, newly
treated by their GP with a phlebotropic drug were enrolled in
the study. They completed a self-questionnaire including the SF-
12, the CES-D and the CIVIQ scales at day zero, day three and
seven. RESULTS: This analysis includes the ﬁrst 399 patients
assessed at inclusion. Mean age was 45.0 years old (SD = 11, n
= 370). A total of 65.7% have a professional activity, 32% prac-
tice sport, 33% are smokers, 78.4% gave birth already and 50%
are under oral contraceptive. A total of 9.1% wear compression
stockings. At inclusion (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4); and the mean
CIVIQ score was 32.6 (SD = 1.1). Concerning the CES-D, the
mean score were 14.9 (SD = 10.2), the results highlighting a 
possible depressive symptomatology in 36.3% of our population
(score 17), and a probable depressive symptomatology in 22.0%
of our population (score 23). CONCLUSIONS: CVD has a great
impact on women. The SF-12 mean scores were below those of
the age- and gender-matched general population. Women with
CVD report greater risk of high depressive symptoms, compared
to the study of Rield where 23.1% of women did (CES-D score
16, age 65 to 75). The impact of CVD on patients daily life is
high even if it seems relative compared to the mean scores
obtained when initially validating the CIVIQ; for example for
patients suffering venous insufﬁciency of lower limb and arteri-
tis mean score was 53.08 (SD = 14.9), unfortunately compari-
son data with patients suffering CVD are lacking.
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OBJECTIVES: The objective of our study was to assess health
status among women suffering from CVD. METHODS: Symp-
tomatic women patients suffering from CVD (CEAP clinical
classes C0 to C4), aged over 18, newly treated by their GP with
a phlebotropic drug were enrolled in the study. Every patient
hadto complete a self-questionnaire including the SF-12 scale 
at day 0, day 3 and day 7. The SF-12 is a generic measure of
health statusThe SF-12 is composed of two dimensions, a Phys-
ical Component Summary (PCS-12) and a Mental component
Summary (MCS-12). The results are standardised on the general
US population (mean score of 50 (SD = 10)) so results for 1 can
be meaningfully compared with the other. The lower the score is
the worse is the impact on patients’ quality of life. RESULTS:
This analysis includes the ﬁrst 399 patients assessed at day 0,
day 3 and day 7. The mean age was 45.0 years old (SD = 11, n
= 370). At inclusion time (n = 374), MCS-12 and PCS-12 were
respectively 44.7 (SD = 10.6) and 46.4 (SD = 8.4): at day 3 and
day 7, these dimensions were respectively: D3: 46.5 (SD = 10.2)
and 46.2 (SD = 8.0) D7: 48.0 (SD = 10.3) and 46.2 (SD = 7.8).
For the mental dimension, the difference was statistically signif-
icant (p = 0.0001). CONCLUSIONS: These results suggest that
CVD has a great impact on women. The SF-12 mean scores were
below those of the age- and gender-matched general population.
The patient management and the use of a phlebotropic drug
demonstrated an improvement on the mental health status of the
patient and a decrease of the impact of pain interfering with
patients normal work.
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OBJECTIVES: The CAMPHOR is the ﬁrst patient-completed
instrument speciﬁc to Pulmonary Arterial Hypertension (PAH).
It consists of separate scales assessing Overall Symptoms (sub-
divided into Energy Level, Breathlessness and Mood sub-scales),
Physical Functioning and Quality of Life (QoL). We report 
ﬁndings from a validation study. METHODS: Patients were
recruited from Papworth Hospital, Cambridge, UK for a postal
survey. They completed the CAMPHOR and the Nottingham
Health Proﬁle (NHP) on the ﬁrst occasion, then two weeks later
completed the CAMPHOR and EQ-5D. Internal consistency was
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assessed using Cronbach’s Alpha and evidence of construct valid-
ity was gained by relating CAMPHOR scores to NHP and EQ-
5D scores and the New York Heart Association Classiﬁcation
(NYHA). RESULTS: In total, 91 patients participated (mean
(SD)) age = 52.6 (16.0) years, 64% female, mean (SD) time since
diagnosis: 4.8 (6.0) years). All CAMPHOR scales obtained ade-
quate alpha coefﬁcients (0.90–0.92), indicating acceptable inter-
nal consistency and Spearman rank correlation coefﬁcients for
all CAMPHOR scales (0.86–0.92) indicated excellent repro-
ducibility. The CAMPHOR also exhibited discriminative valid-
ity, as the questionnaire was able to distinguish between patients
who differed according to self-perceived general health (p <
0.001), symptom level (p < 0.001) and NYHA classiﬁcation (p
< 0.001). The level of association was as expected, with more
closely related scales having higher levels of association (NHP
Energy Level with CAMPHOR Energy Level = 0.84; NHP 
emotional reactions and CAMPHOR mood = 0.84 and 
NHP physical mobility and CAMPHOR functioning = 0.85).
The EQ-5D also correlated most closely with CAMPHOR func-
tioning (0.74), which was anticipated, as 3 of the 5 EQ-5D items
relate to functioning. CONCLUSIONS: The results of the vali-
dation study provide evidence that the instrument will be able to
detect changes in HRQL and QoL occurring in routine clinical
practice and clinical trials, indicating that the CAMPHOR is a
valuable new instrument for assessing patient-reported outcome
in PAH.
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Isolated by language and cultural beliefs, Chinese immigrants
face formidable barriers to receiving appropriate health care ser-
vices. In the absence of preventive care, common treatable
disease such as high blood pressure (BP) becomes much more
dangerous and severe. OBJECTIVES: Assess trends in the preva-
lence, awareness, treatment, and control of hypertension among
Chinese immigrants in New York City (NYC). METHODS:
Using a standardized survey, BP measurements and health infor-
mation of participants aged 18 years or older were collected
during a series of community health fairs in various Chinese
communities. The 2001–2002 survey (N = 668) was compared
to 2003–2004 survey (N = 791). Hypertension is deﬁned as a
measured BP of >140/90mmHg or reported use of antihyper-
tensive medications. Hypertension awareness and treatment
were assessed with standardized questions. Hypertension control
was deﬁned as reported hypertension with or without antihy-
pertensive treatment and a measured BP of <140/90mmHg or
<130/85mmHg for diabetics. RESULTS: In 2003–2004, 44% of
participants had hypertension, a decrease of 5% (p = 0.058) from
2001–2002. Hypertension prevalence was higher in women
(25%) and increased with age (31% among those aged >60
years). In a Pearson correlation analysis, increasing age and
decreasing exercise were independently associated with increased
rates of systolic blood pressure (SBP) but not diastolic blood
pressure (DBP); increasing body mass index was independently
associated with increased in both SBP and DBP. Overall, in
2003–2004, 71% were aware of their hypertension (a decline of
1%; p < 0.737), 26% were treated (decrease of 8%; p = 0.017),
and hypertension was controlled in 40% (increase of 2%; p =
0.645). Men and those aged 40–59 had lower rates of hyper-
tension treatment and control compared with women and the
older individuals. CONCLUSIONS: Although prevalence and
control rates of hypertension are improving, hypertension
control rates continue to be low. Expanded effort is needed to
improve BP outcomes.
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OBJECTIVES: Visual analogue scaling (VAS) is a rating method,
widely used to estimate preferences for multi-attribute health
states. This study examines the ability of VAS preferences to dis-
criminate between severity levels in stroke-related disability
deﬁned by the Barthel Index (BI). METHODS: A community
sample of 152 adults (≥45 years) were instructed by trained
researchers to ﬁrst rank and then rate 14, 5-attribute disability
scenarios on a 20-point rating thermometer (0 = worst imagin-
able health state; 20 = best imaginable health state). Preferences
for Barthel Index disability scores were estimated from ordinary
least squares regression (OLS) and indexed on a scale of 0–1.
Discriminant validity of the VAS preferences was evaluated using
two BI severity categorization schemes, modiﬁed Rankin cate-
gories, and two BI endpoint categories used in clinical trials (<95
vs. ≥95 and <60 vs. ≥60). RESULTS: The VAS preferences dis-
criminated between severity levels in physical disability in each
of the ﬁve cases against which they were tested. Preferences
ranged from 0.00–0.12 for total dependence (BI = 0–20), from
0.06–0.43 for severe dependence (BI = 25–60), from 0.46–0.84
for moderate dependence (BI = 65–90), and from 0.87–1.00 for
independence (BI = 95–100). For a ﬁve-category physical dis-
ability severity scheme, preferences ranged from 0.00–0.12 for
very severe (BI = 0–20), 0.06–0.30 for severe (BI = 25–45),
0.30–0.69 for moderate (BI = 50–70), 0.59–0.92 for mild phys-
ical disability (BI = 75–95). Preferences associated with modiﬁed
Rankin scores were 0.00–0.18 for category 5 (severe handicap);
0.24–0.46 for category 2 (moderately severe handicap);
0.69–0.84 for category 3 (moderate handicap), and 0.87–1.00
for categories 0–2 (no symptoms to minor handicap). Preferences
for BI scores <95 vs. ≥95 were 0.00–0.84 vs. 0.87–1.00 vs.
respectively, and for BI scores <60 vs. ≥60 were 0.00–0.43 vs.
0.43–1.00, respectively. CONCLUSIONS: VAS preferences were
found to relate directly to disability severity and may be useful
in distinguishing between different physical disability levels in
stroke patients.
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OBJECTIVES: The Cambridge Pulmonary Hypertension
Outcome Review (CAMPHOR) is the ﬁrst validated patient-
completed measure for assessing outcome in Pulmonary Hyper-
tension (PH). It consists of separate scales assessing Overall
Symptoms, Energy Level, Breathlessness, Mood, Physical Func-
tioning and Quality of Life (QoL). This study compares the rel-
ative performance of the CAMPHOR with that of generic
